Palvella Therapeutics Reports Q3 GAAP EPS of -$1.70, Exceeding Estimates
Palvella Therapeutics (NASDAQ: PVLA) reported third-quarter GAAP earnings per share of -$1.70, which outperformed analyst expectations by $0.07. The company maintains a strong liquidity position, reporting $236.7 million in cash, cash equivalents, and short-term investments as of September 30, 2024. The market reaction has been bolstered by positive regulatory developments regarding the company's lead asset, which has received FDA priority review. This regulatory progress is viewed as a potential catalyst for commercializing treatments within the rare disease sector.
Tickers: $PVLA
Topics: cash position earnings beat FDA priority review GAAP EPS